N,N- dipropyl- N'- (4- ((((1H- imidazol- 2- yl)methyl)((1- methyl- 1H- imidazol- 2- yl) methyl)amino)methyl)benzyl)- N'- methylbutane- 1,4- diamine

an anti-HIV agent

Also Known As:

KRH 3955; KRH-3955; KRH3955

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Benzylamines: 10
    - N,N-dipropyl-N'-(4-((((1H-imidazol-2-yl)methyl)((1-methyl-1H-imidazol-2-yl) methyl)amino)methyl)benzyl)-N'-methylbutane-1,4-diamine: 4
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzyl Compounds: 2
        Benzylamines: 10
        N,N-dipropyl-N'-(4-((((1H-imidazol-2-yl)methyl)((1-methyl-1H-imidazol-2-yl) methyl)amino)methyl)benzyl)-N'-methylbutane-1,4-diamine: 4
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - N,N-dipropyl-N'-(4-((((1H-imidazol-2-yl)methyl)((1-methyl-1H-imidazol-2-yl) methyl)amino)methyl)benzyl)-N'-methylbutane-1,4-diamine: 4

Experts

1.	Kumakura, Sei: 3 articles (04/2013 - 04/2009)
2.	Murakami, Tsutomu: 3 articles (04/2013 - 04/2009)
3.	Yamamoto, Naoki: 3 articles (04/2013 - 04/2009)
4.	Yanaka, Mikiro: 2 articles (07/2009 - 04/2009)
5.	Nakasone, Tadashi: 1 article (04/2013)
6.	Yamamoto, Michiko: 1 article (04/2013)
7.	Iwanaga, Tomohiro: 1 article (11/2012)
8.	Iwasaki, Yoshiaki: 1 article (11/2012)
9.	Matsumoto, Hiroshi: 1 article (11/2012)
10.	Nakano, Daisuke: 1 article (11/2012)

Related Diseases

1.	Infections 04/01/2013 - "These results show that natural course of the SHIV infection is modulated by artificial increase of neutrophils and lymphocytes caused by KRH-3955 in the cynomolgus monkey model." 04/01/2013 - "The SHIV infection studies using the SHIV-KS661c/cynomolgus monkey model showed that a single oral administration of KRH-3955 (100 mg/kg) approximately 24 h before virus exposure did not prevent infection, although it did prevent CD4 cell depletion in 3/3 monkeys. " 07/01/2009 - "Thus, KRH-3955 is a new promising agent for HIV-1 infection and AIDS." 07/01/2009 - "The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100." 04/01/2009 - "Taken together, the KRH-1636 derivatives KRH-2731 and KRH-3955 may be promising as a novel inhibitory drug for cancer metastasis as well as for human immunodeficiency virus type 1 infection."
2.	Neoplasms (Cancer) 11/01/2012 - "The mean weights of the tumors were 7.092±1.221 g in the control mice, 5.137±1.001 g in the ADM3100-injected mice, 3.895±2.120 g in mice treated with 1 mg/kg of KRH3955, and 4.257±1.169 g in mice treated with 10 mg/kg of KRH3955. " 11/01/2012 - "The CXCR4 blockers AMD3100 and KRH3955 inhibit tumor growth in vivo. " 04/01/2009 - "Taken together, the KRH-1636 derivatives KRH-2731 and KRH-3955 may be promising as a novel inhibitory drug for cancer metastasis as well as for human immunodeficiency virus type 1 infection."
3.	Neoplasm Metastasis (Metastasis) 04/01/2009 - "Taken together, the KRH-1636 derivatives KRH-2731 and KRH-3955 may be promising as a novel inhibitory drug for cancer metastasis as well as for human immunodeficiency virus type 1 infection."
4.	Acquired Immunodeficiency Syndrome (AIDS) 07/01/2009 - "Thus, KRH-3955 is a new promising agent for HIV-1 infection and AIDS."

Related Drugs and Biologics

1.	plerixafor
2.	KRH 1636

Related Therapies and Procedures

1.	Oral Administration